|March 25, 2013|
|04:55 EDT||CTRX, CTRX, AET, AET, ESRX, ESRX, AVNR, AVNR, VVUS, VVUS, CVS, CVS||Pharmaceutical Care Management Association to host a summit|
PBM Summit is being held in Las Vegas on March 25-26.
News For CTRX;AET;ESRX;AVNR;VVUS;CVS From The Last 14 Days
Check below for free stories on CTRX;AET;ESRX;AVNR;VVUS;CVS the last two weeks.
|August 29, 2014|
|13:22 EDT||ESRX||Express Scripts management to meet with SunTrust|
Meeting to be held in New York on September 4 hosted by SunTrust.
|August 27, 2014|
|08:33 EDT||CVS||CVS Caremark announces new clinical affiliation with MedStar Health|
Subscribe for More Information
|August 26, 2014|
|09:02 EDT||AVNR||Concert Pharmaceuticals achieves $2M milestone for AVP-786|
Concert Pharmaceuticals (CNCE) announced that it has achieved a $2M milestone under its development and license agreement with Avanir Pharmaceuticals (AVNR) for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. The agreement provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan compounds. The licensed compounds are believed to have potential for the treatment of neurological and psychiatric disorders. Under the agreement, Concert is eligible to receive additional milestone payments based upon achievement of certain predefined clinical, regulatory and commercial targets. Avanir will continue to have overall responsibility for research, development and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive tiered royalties on worldwide sales of any products containing d-DM. The milestone announced today is the second development milestone Concert has earned under the agreement.
|09:02 EDT||AVNR||Avanir initiates AVP-786 phase II study|
Subscribe for More Information
|August 25, 2014|
|07:59 EDT||CTRX||Some healthcare providers offer compelling opportunities, says Jefferies|
Jefferies believes that the following healthcare providers reported good Q2 results which have not been adequately reflected by their stocks: Acadia Healthcare (ACHC), Almost Family (AFAM), Brookdale Senior Living (BKD), Catamaran (CTRX), Community Health (CYH), Envision Healthcare (EVHC), and HCA Holdings (HCA). The firm expects the sector as a whole to continue to improve in 2H14 amid continued tailwinds from healthcare reform.
|07:03 EDT||VVUS||VIVUS acquires patents from Janssen Pharmaceuticals |
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
|August 24, 2014|
|21:53 EDT||CVS||National Association of Chain Drug Stores to hold an expo|
2014 NACDS Total Store Expo to be held in Boston on August 23-25.
|August 22, 2014|
|12:39 EDT||AVNR||These five companies will benefit from increased ALS awareness, MarketWatch says|
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
|August 18, 2014|
|08:31 EDT||CVS||CVS Caremark's Accordant Health receives NCQA accreditation|
CVS Caremark announced that its Accordant Health Services division has received full NCQA Patient and Practitioner Oriented Disease Management accreditation for programs to support: Epilepsy, Rheumatoid Arthritis, Multiple Sclerosis, Crohn's Disease, Ulcerative Colitis, Parkinson's Disease, Systemic Lupus Erythematosus, Myasthenia Gravis, Sickle Cell Disease, Cystic Fibrosis, Hemophilia, Scleroderma, Polymyositis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Amyotrophic Lateral Sclerosis, Dermatomyositis, and Gaucher Disease.